comparemela.com

Latest Breaking News On - Fast track drug - Page 1 : comparemela.com

Celsion Corporation Provides Clinical Update on Phase I/II OVATION 2 Study with GEN-1 in

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Celsion Corporation Provides Clinical Update on Phase I/II OVATION 2 Study with GEN-1 in . Celsion CORPFebruary 25, 2021 GMT Of 27 patients who completed interval debulking surgery, 80% of those treated with GEN-1 had an R0 resection compared with 58% of control patients, a 38% improvement To date 34 patients, or approximately one-third of the total, have been enrolled at 22 sites, including 20 patients in the treatment arm and 14 patients in the control arm LAWRENCEVILLE, N.J., Feb. 25, 2021 (GLOBE NEWSWIRE) Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, today provided an update on its Phase I/II OVATION 2 Study with GEN-1 in patients with advanced ovarian cancer, including interim observations. GEN-1 is Celsion’s DNA-mediated interleukin-12 (IL-12) immunotherapy designed using TheraPlas, it

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.